ATG 037 and pembrolizumab study stays recruiting in advanced solid tumors
A phase 1 ClinicalTrials.gov registry observation shows ATG 037 with pembrolizumab is still recruiting for advanced solid tumors, with safety and dose-finding outcomes still ahead.
A phase 1 cancer study of ATG 037 with pembrolizumab is still recruiting, according to a ClinicalTrials.gov registry observation published 2026-11-10T00:00:00+00:00. For people following advanced solid tumors, the immediate takeaway is simple: this study is open, early, and still gathering the safety and dose information that comes first in this kind of research.
The study title says it is looking at the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ATG 037 monotherapy and combination therapy with pembrolizumab in patients with advanced solid tumors. The registry lists Antengene Therapeutics Limited as sponsor, gives the overall status as RECRUITING, and says no results have been posted.
This record describes a study and its registry status; study outcomes require posted results.
What the trial is measuring
The primary outcomes are focused on early-stage trial questions. Those include the incidence of adverse events and server adverse events, dose limiting toxicity, maximum tolerated dose of ATG-037, and the recommended phase 2 dose of ATG-037.
The timing also shows how early this work is. The registry lists some outcomes at up to 21 Days, while adverse events are tracked One year after last patient first dose, which means the study is built to watch both short-term tolerability and longer safety follow-up.
How ATG 037 is being studied
The clinical contract shows one experimental arm labeled ATG-037+Keytruda(Pembrolizumab, MK-3475), with ATG-037 and KEYTRUDA ®( Pembrolizumab) both named as interventions. Allocation is listed as NA, so the registry does not describe a randomized split here.
The estimated primary completion date is 2027-08-30. That is the clearest current timeline in the registry, and it means the main readout is still ahead rather than settled now.
Why this fits the wider cancer-breakthroughs picture
This study appears inside the active Cancer Breakthroughs special event, alongside other cancer-related registry observations that are moving through recruiting, active not recruiting, or not yet recruiting stages. Taken together, those entries show a busy clinical-trial picture without implying that they answer the same question in the same way.
For readers scanning for the next development, the useful point is that ATG 037 remains in the early phase of testing and still seeks basic evidence on safety and dosing before any stronger claim about benefit can be made. Until posted results appear, the registry only supports a live trial in progress, not an outcome.